GILD · 10-Q · 2026Q3 · Full report
Acquisition and Restructuring
GILEAD SCIENCES, INC. · 2026-10-30 · Importance 65 · Surprise 60 · Contradicted
Acquired in-process research and development expenses totaled $11.3 billion for the nine months ended September 30, 2026, primarily reflecting $7.0 billion for Arcellx, $3.1 billion for Tubulis and $1.0 billion net for Ouro Medicines after Lakefront’s $860 million share of the upfront consideration. The company also recorded $80 million for its Suzhou Genhouse collaboration. Gilead completed acquisitions of Arcellx, Tubulis and Ouro Medicines in the second quarter of 2026; the deals added oncology and inflammation programs, including anito-cel and gamgertamig. No restructuring charge or headcount reduction is identified in the provided MD&A text.
Key facts
- Gilead incurred $11.3 billion of acquired IPR&D expenses for the nine months ended September 30, 2026, primarily including $7.0 billion for Arcellx, $3.1 billion for Tubulis, $1.0 billion for Ouro Medicines and $80 million for the Suzhou Genhouse collaboration. source
- Gilead’s acquisition of Ouro Medicines involved $1.9 billion of acquisition cost, partly offset by $860 million for Lakefront’s share of upfront consideration, resulting in $1.0 billion of acquired IPR&D expense. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | realized | -136.1% | Gilead incurred $11.3 billion of acquired IPR&D expenses for the nine months ended September 30, 2026, primarily including $7.0 billion… |
| operating_income | negative | realized | -12.1% | Gilead’s acquisition of Ouro Medicines involved $1.9 billion of acquisition cost, partly offset by $860 million for Lakefront’s share of… |